Abstract
Aberrant activation of transglutaminase 2 (TGase2) contributes to a variety of protein conformational disorders such as neurodegenerative diseases and age-related cataracts. The accumulation of improperly folded proteins in the endoplasmic reticulum (ER) triggers the unfolded protein response (UPR), which promotes either repair or degradation of the damaged proteins. Inadequate UPR results in protein aggregation that may contribute to the development of age-related degenerative diseases. TGase2 is a calcium-dependent enzyme that irreversibly modifies proteins by forming cross-linked protein aggregates. Intracellular TGase2 is activated by oxidative stress which generates large quantities of unfolded proteins. However, the relationship between TGase2 activity and UPR has not yet been established. In the present study, we demonstrated that ER stress activated TGase2 in various cell types. TGase2 activation was dependent on the ER stress-induced increase in the intracellular calcium ion concentration but not on the TGase2 protein expression level. Enzyme substrate analysis revealed that TGase2-mediated protein modification promoted protein aggregation concurrently with decreasing water solubility. Moreover, treatment with KCC009, a TGase2 inhibitor, abrogated ER stress-induced TGase2 activation and subsequent protein aggregation. However, TGase2 activation had no effect on ER stress-induced cell death. These results demonstrate that the accumulation of misfolded proteins activates TGase2, which further accelerates the formation of protein aggregates. Therefore, we suggest that inhibition of TGase2 may be a novel strategy by which to prevent the protein aggregation in age-related degenerative diseases.
Keywords: unfolded protein response, transglutaminase 2, αB-crystallin, protein aggregation, HLE-B3
Introduction
Aberrant accumulation of protein aggregates is a key characteristic of several age-related degenerative disorders (1). During life, cells are chronically exposed to oxidative stress resulting from mitochondrial inefficiency or dysfunction, which can cause a variety of oxidative modifications to proteins such as thiolation, glycation, phosphorylation and deamidation (2). The oxidatively damaged proteins are prone to form into tangled aggregates by non-enzymatic reaction unless they are degraded by the ubiquitin-proteasome system in a timely manner (3).
Transglutaminase 2 (TGase2) is a member of a family of enzymes that post-translationally modify proteins by catalyzing an acyl transfer reaction between the γ-carboxamide group of protein glutamine residues and the ɛ-amino group of lysine residues (protein cross-linking), or polyamines (protein polyamination) (4). The transamidation activity of TGase2 is calcium-dependent and produces irreversible protein polymers that are resistant to proteolytic degradation (5). Thus, TGase2 plays a crucial role in the formation of insoluble protein aggregates and has been implicated in the pathogenesis of many diseases termed ‘conformational diseases’ (4). For example, TGase2 may contribute to the formation of crystallin polymers in age-related cataracts (6), the aggregation of huntingtin protein with an expanded polyglutamine domain as occurs in Huntington’s disease (7), and the accumulation of insoluble neurofibrillary tangles and β-amyloid plaques in Alzheimer’s disease (8,9). We recently demonstrated that reactive oxygen species (ROS) activate intracellular TGase2 in various cell types (10) and that the transforming growth factor β (TGFβ) signaling pathway is involved in TGase2 activation (11). However, the role of TGase2 in cellular responses to other stressors remain to be elucidated.
The accumulation of misfolded proteins in the endoplasmic reticulum (ER) can trigger a specific stress response called the unfolded protein response (UPR) (12). Accordingly, several chemical inhibitors of protein folding procedures such as tunicamycin (TM; inhibitor of N-glycosylation), dithiothreitol (DTT) or β-mercaptoethanol (β-ME; permeable reducing agents), and thapsigargin (TG; inhibitor of the Ca2+ pump in ER) induce the UPR response. The UPR pathway is important for regulation of normal cellular homeostasis and may also play key roles in the pathology of conformational diseases (13). Cells can employ different UPR programs depending on the level of ER stress (14). In response to moderate stress, cells reduce the cellular burden of improperly folded proteins by attenuating de novo protein synthesis through phosphorylation of the protein translation initiation factor 2 (eIF2α) and by inducing the expression of chaperone proteins, including several glucose response proteins (GRPs). By contrast, sustained and unresolved ER stress may trigger programmed cell death through activation of activating transcription factor 4 (ATF4), ATF6, CCAAT/enhance-binding protein homologous protein (CHOP) and caspases (12,13,15,16). Moreover, at the cellular level, ER stress induces an increase in intracellular Ca+ concentration and ROS generation (14,17). Of note, these intracellular conditions are known to activate in situ transamidation activity of TGase2 (10,11,18,19), suggesting that the aggregate formation of misfolded proteins is accelerated by TGase2-mediated protein modifications. Thus, it is reasonable to investigate the likely relationship between protein misfolding stress and TGase2 activity. In the present study, we found that ER stress induces TGase2 activation in various cell types, including lens epithelial cells, and that the activated enzyme plays a critical role in the formation of protein aggregates.
Materials and methods
Cell culture
Human lens epithelial (HLE-B3), erythroleukemia (K562), cervical carcinoma (HeLa), and neuroblastoma (SH-SY5Y) cell lines were cultured as previously described (10). For UPR activators, cells were treated with culture media containing β-ME (Sigma, St. Louis, MO, USA; 7.5 mM), DTT (Sigma; 3 mM), TG (Sigma; 1 mM) or TM (Sigma; 5 μg/ml) for the indicated times and then maintained in culture until analysis. KCC009, a specific chemical inhibitor of TGase2 (20), was added at a concentration of 125 μM to inhibit transamidation activity. To differentiate SH-SY5Y cells, the cells were treated with 5 μM retinoic acid (RA) (Sigma) for 1 day before induction of ER stress.
Measurement of intracellular calcium
Ca2+ levels were measured by fluorimetry using the Fluo-4AM (Molecular Probes, Carlsbad, CA, USA). Approximately 3×104 cells were grown overnight in a 96-well microplate. After exposure to ER stress, the cells were incubated with 100 μl of assay buffer (Hanks’ balanced salt solution in 20 mM HEPES, pH 7.4) containing 5 μM Fluo-4AM at 37°C for 30 min and for an additional 30 min at room temperature. The cells were then washed with the assay buffer 4 times, and then the intensity of fluorescence was measured using a fluorescence microplate reader (Cary Eclipse; Varian, Palo Alto, CA, USA) with excitation set at 488 nm and emission set at 516 nm. After reading, the cells were stained with crystal violet (Sigma) to normalize the fluorescence value. Intracellular Ca2+ levels were expressed as the ratio of values in ER stress-exposed cells to that of untreated cells. EGTA (1.5 mM) and BAPTA-AM (20 μM, Molecular Probes) were used for calcium chelation.
In situ transamidation assays
In situ TGase2 activity was measured by determining the biotinylated pentylamine (BP) incorporated into cellular proteins. Cells were incubated with 1 mM BP (Pierce, Rockford, IL, USA) for 1 h prior to harvesting, and then the cell extracts were prepared by sonication in phosphate-buffered saline (PBS) with a protease inhibitor cocktail, followed by centrifugation (14,000 × g, 10 min at 4°C). For the solid-phase microtiter plate assay, cell extracts (0.2 mg/ml, 50 μl/well) in coating buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 5 mM EGTA, 5 mM EDTA) were added to each well of a 96-well microtiter plate. In situ TGase2 activity was evaluated by determining the incorporated BP using HRP-conjugated streptavidin (Pierce), followed by reaction with O-phenylenediamine dihydrochloride (Sigma). Assays were quantified by measuring the absorbance at 490 nm on a microplate spectrophotometer (Molecular Devices). In situ TGase2 activities were normalized by subtracting values representing endogenous biotin-conjugated proteins that were obtained without the addition of biotinylated pentylamine. In situ TGase2 activity was presented as folds of activation, compared to non-treated experiments. Western blot analysis was performed by subjecting the cell extracts (30 μg) to SDS-PAGE using a 12% gel, and the proteins were then transferred to nitrocellulose membranes. The proteins incorporated with BP were probed with HRP-conjugated streptavidin, followed by chemiluminescence detection (Pierce).
Western blotting
The cell extracts (30 μg) were separated on 12% SDS-PAGE gels following preparation in RIPA lysis buffer (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Protein levels were assessed by probing with monoclonal antibodies specific for TGase2 (21) and β-actin (Santa Cruz Biotechnology, Inc.). To investigate the TGase2-catalyzed crosslinking of lens proteins, whole cell extracts were prepared by sonication in homogenate buffer (50 mM Tris-Cl, pH 6.8, 6 M urea, 2% SDS, 40 mM DTT and a protease inhibitor cocktail) and further centrifuged at 12,000 × g for 10 min at 4°C. Proteins were quantified using the BCA method (Pierce), resolved on 6–15% SDS-PAGE gels, and subsequently analyzed using antibodies specific for αB-crystallin (Stressgen) and vimentin (Santa Cruz Biotechnology, Inc.). For the solubility experiments, cell extracts were separated into the water-soluble and water-insoluble fractions as previously described (11).
Cell viability assay
Cell viability after treatment with UPR stress was determined by MTT assay (Sigma) according to the manufacturer’s protocol. The reduction of MTT reagent was quantified after 4 h by measuring the absorbance at 570 nm on a microplate spectrophotometer (Molecular Devices).
Statistical analysis
All data on TGase2 activity and cell viability were analyzed using one-way or two-way ANOVA with Bonferroni post-tests. All analyses were performed using GraphPad Prism 5.0 statistical software (GraphPad Software, La Jolla, CA, USA). Statistical significance was defined as p<0.05 or p<0.01.
Results
The aberrant activation of TGase2 accelerates the pathological misfolding/aggregation of proteins (10,11). To test whether ER stress activates TGase2, we measured the intracellular transamidation activity in the HLE-B3 cells following treatment with β-ME. In situ activity of TGase2 was monitored by incubating the cells with BP and by measuring the BP-incorporated proteins in the cell extracts using a well plate or SDS-PAGE assay. As shown in Fig. 1A and B, treatment with β-ME significantly increased intracellular TGase2 activity, peaking at 4 h after treatment. The level of TGase2 protein was little affected under this condition (Fig. 1B), suggesting that latent TGase2 present under normal culture conditions was activated by ER stress as previously observed in the case of the oxidative stress (10,11). In addition, treatment with KCC009, a chemical inhibitor for TGase2 abrogated the β-ME-induced increase of TGase2 activity (Fig. 1C).
We next evaluated whether other ER stress-causing agents affect the TGase2 activity in HLE-B3 cells. As shown in Fig. 2, in situ TGase2 activity was similarly increased with little change in the protein levels following treatment with most UPR activators, including DTT, TG, and TM. Supra-physiological stressors, such as DTT and β-ME, rapidly increased the TGase2 activity at ~4 h. By contrast, treatment with TG or TM reached a peak of induced enzyme activity by 24 h, indicating that each ER stress exhibited distinct TGase2 activation kinetics. Since the transamidation activity of TGase2 is calcium-dependent (22), intracellular calcium concentrations were measured following treatment with different ER stress inducers. In correlation with the observed time-dependent rise in TGase2 activity, Ca+ concentrations in HLE-B3 cells rapidly increased with DTT, but increased more gradually over 24 h following TG or TM treatment (Fig. 3A). In addition, Ca2+ chelation by BAPTA-AM or EGTA abrogated the effect of TM on TGase2 activity (Fig. 3B and C), indicating that an elevated intracellular Ca2+ concentration is required for enzyme activation. The increased TGase2 activity stimulated by DTT was partially attenuated by the presence of EGTA; however it was little affected by treatment with BAPTA-AM (Fig. 3B and D). The TGase2 protein level was also similar in all of the conditions tested. Therefore, these results demonstrate that UPR increases intracellular calcium ion concentrations that activate TGase2.
To gain insight into the potential pathophysiological roles of TGase2, we evaluated whether TGase2 modifies individual lens proteins upon ER stress. To address this issue, proteins cross-linked with BP by TGase2 were isolated using streptavidin pull-down and subjected to western blot analysis. BP modification of αB-crystallin and vimentin was observed specifically in cells treated with TM or TG, but it was inhibited by treatment with KCC009 (Fig. 4A). Previous studies report that the lens proteins modified by TGase2 in response to oxidative stress or TGFβ stimulation were dimerized and showed decreased water solubility (10,11). Similarly, treatment with each UPR activator tested led to the formation of high-molecular-weight protein of αB crystallin, but not vimentin (Fig. 4B). When the cell extracts were separated into water soluble and insoluble fractions, both αB crystallin and vimentin proteins in the water-insoluble fraction increased in the cells exposed to ER stress (Fig. 4C). Moreover, KCC009 significantly inhibited the protein cross-linking and water insolubility of lens proteins stimulated by treatment with TG and TM, but not DTT (Fig. 4B and C). These results demonstrate that the activation of TGase2 under ER stress conditions plays a pivotal role in the formation of water-insoluble aggregates of lens proteins.
Next, we investigated whether ER stress activates TGase2 in other types of cells. As shown in Fig. 5, ER stress inducers increased TGase2 intracellular activity in most of the cell types evaluated, including human erythrocarcinoma (K562; Fig. 5A and B), cervical cancer (HeLa; Fig. 5C) and neuroblastoma (SH-SY5Y; Fig. 5D) cell lines. These results indicate that the activation of TGase2 is not specific to lens epithelial cells. Moreover, treatment of SH-SY5Y cells with retinoic acid (RA) induced the expression of TGase2, and it may play an important role in cell survival (23–25). When SH-SY5Y cells were pre-treated with RA, the protein level of TGase2 increased (Fig. 5E). Under this condition, ER stress further increased in situ TGase activity in SH-SY5Y cells (Fig. 5D). When cell viability was evaluated following exposure to ER stress, little significant difference in cell death was noted between non-treated and RA-treated SH-SY5Y cells (Fig. 5F), suggesting that UPR-induced cell death was independent of TGase2-mediated protein aggregation.
Discussion
The present study demonstrated that ER stress activates transglutaminase 2 (TGase2) in several cell types which subsequently plays a causal role in the formation and accumulation of intracellular protein aggregates. The TGase enzyme family consists of 8 enzymes, TGase1 to TGase7, and Factor XIIIa. Each TGase isoenzyme shows a restricted pattern of tissue distribution where it plays a specific function, such as the formation of the barrier structure in skin (TGase1, TGase3 and TGase5), formation of fibrin aggregates in blood clots (coagulation Factor XIIIa), and generation of the post-coital plug of seminal fluid (TGase4) (26–28). By contrast, TGase2 is unique among the TGase family members in its ubiquitous tissue expression and widespread subcellular localization (22). In the lens epithelium, TGase2 is the major TGase isoform and was found to induce the formation of lens protein aggregates in response to UV-irradiation and oxidative stress in a lens organ culture model of cataract (11,29). In the present study, we showed that several of the ER stress-causing agents tested increased the in situ transamidation reaction in lens epithelial cells (Figs. 1 and 2). Moreover, ER stress-induced protein aggregation was reduced by treatment with a chemical inhibitor for TGase2 (Fig. 1C). These results demonstrate that unfolded or misfolded proteins produced by oxidative stress activate TGase2 leading in the accumulation of protein aggregates.
Previous studies have shown that intracellular TGase2 activity does not correlate with its protein expression level and that TGase2 activation is cell type-dependent (10). Under normal culture conditions, intracellular TGase2 activity was not observed in lens epithelial cells despite of the high TGase2 protein level (Figs. 1 and 2), indicating that control of this enzyme is tightly regulated in the intracellular environment. The transamidation reaction of TGase2 is dependent on the intracellular calcium level (30). UPR activators evaluated here increased the intracellular concentration of Ca2+, and Ca2+ chelation prevented TGase2 activation by UPR (Fig. 3A and B), indicating that the rise in intracellular Ca2+ could explain the observed increase in TGase2 activity despite of little change in its protein level. However, DTT treatment activated TGase2 even in the presence of BAPTA-AM (Fig. 3B and C), suggesting that other cellular factor(s) may be involved in the regulation of TGase2 activity in response to DTT treatment.
In the present study, we employed a lens epithelial cell line to investigate the role of TGase2 in the formation of intracellular aggregates of misfolded proteins. For this purpose, lens tissue may provide several advantages since lens epithelial cells have a much simpler protein complexity and accumulate oxidatively modified proteins without degradation (31). A single layer of lens epithelial cells differentiates into fiber cells, which make up the lamellae inside the lens without replacing the older fiber cells (31). The misfolding of lens proteins such as crystallins and vimentin is easily monitored using dimerization and water-solubility as assessed by western blotting (Fig. 4). Moreover, lens protein aggregation can be easily detected by the development of lens opacity (11). Thus, ex vivo lens organ culture and in vivo animal models may be excellent systems for the development of pharmaceuticals that inhibit the protein aggregation caused by a variety of forms of cellular stress.
Our results showed that TGase2 was also activated by ER stress in other cell types including neuroblastoma cells. Of note, it is known that TGase2 post-translationally modifies several aggregation-prone proteins such as amyloid β-peptide, tau, α-synuclein and huntingtin (7–9,32). In particular, treatment with cystamine, a TGase inhibitor (33), or ablation of TGase2 (34) delays the onset of neurological symptoms and improves the life expectancy of Huntington’s disease model mice, suggesting that aberrant activation of TGase2 may be involved in the formation of insoluble aggregates in neurons through protein modification during ageing. Several studies have indicated that the induction of TGase2 during RA-mediated differentiation plays a protective role against neuroblastoma cell death following exposure to excitotoxic or inflammatory stress (23,24). However, another study reported that TGase2 enhanced β-amyloid 1–42-induced apoptosis (25). In the present study, RA pre-treatment had little effect on the viability of SH-SY5Y cells exposed to ER stress (Fig. 5F). Thus, further study on the unknown cellular function(s) of TGase2-mediated protein aggregation under stress conditions is required to precisely understand the pathophysiological role of this enzyme.
Acknowledgements
This study was partly supported by a grant from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (2012R1A1A1004438), and grants from the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A120301 to D.-M.S. and A100190 to I.-G.K.).
References
- 1.Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature. 2011;475:324–332. doi: 10.1038/nature10317. [DOI] [PubMed] [Google Scholar]
- 2.Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787–795. doi: 10.1038/nature05292. [DOI] [PubMed] [Google Scholar]
- 3.Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 2001;292:1552–1555. doi: 10.1126/science.292.5521.1552. [DOI] [PubMed] [Google Scholar]
- 4.Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol. 2003;4:140–156. doi: 10.1038/nrm1014. [DOI] [PubMed] [Google Scholar]
- 5.Klöck C, Khosla C. Regulation of the activities of the mammalian transglutaminase family of enzymes. Protein Sci. 2012;21:1781–1791. doi: 10.1002/pro.2162. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Prasanna Murthy SN, Velasco PT, Lorand L. Properties of purified lens transglutaminase and regulation of its transamidase/crosslinking activity by GTP. Exp Eye Res. 1998;67:273–281. doi: 10.1006/exer.1998.0509. [DOI] [PubMed] [Google Scholar]
- 7.Jeitner TM, Bogdanov MB, Matson WR, et al. Nɛ-(γ-l-Glutamyl)-l-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington’s disease. J Neurochem. 2001;79:1109–1112. doi: 10.1046/j.1471-4159.2001.00673.x. [DOI] [PubMed] [Google Scholar]
- 8.Konno T, Morii T, Hirata A, Sato S, Oiki S, Ikura K. Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking. Biochemistry. 2005;44:2072–2079. doi: 10.1021/bi047722d. [DOI] [PubMed] [Google Scholar]
- 9.Halverson RA, Lewis J, Frausto S, Hutton M, Muma NA. Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice. J Neurosci. 2005;25:1226–1233. doi: 10.1523/JNEUROSCI.3263-04.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Shin DM, Jeon JH, Kim CW, et al. Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation: implications of transglutaminase 2 in age-related cataractogenesis. J Biol Chem. 2004;279:15032–15039. doi: 10.1074/jbc.M308734200. [DOI] [PubMed] [Google Scholar]
- 11.Shin D-M, Jeon J-H, Kim C-W, et al. TGFβ mediates activation of transglutaminase 2 in response to oxidative stress that leads to protein aggregation. FASEB J. 2008;22:2498–2507. doi: 10.1096/fj.07-095455. [DOI] [PubMed] [Google Scholar]
- 12.Moore KA, Hollien J. The unfolded protein response in secretory cell function. Annu Rev Genet. 2012;46:165–183. doi: 10.1146/annurev-genet-110711-155644. [DOI] [PubMed] [Google Scholar]
- 13.Lin JH, Walter P, Yen TS. Endoplasmic reticulum stress in disease pathogenesis. Annu Rev Pathol. 2008;3:399–425. doi: 10.1146/annurev.pathmechdis.3.121806.151434. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Schröder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem. 2005;74:739–789. doi: 10.1146/annurev.biochem.73.011303.074134. [DOI] [PubMed] [Google Scholar]
- 15.Xin W, Li X, Lu X, Niu K, Cai J. Involvement of endoplasmic reticulum stress-associated apoptosis in a heart failure model induced by chronic myocardial ischemia. Int J Mol Med. 2011;27:503–509. doi: 10.3892/ijmm.2011.612. [DOI] [PubMed] [Google Scholar]
- 16.Wu LF, Wei BL, Guo YT, et al. Apoptosis induced by adenosine involves endoplasmic reticulum stress in EC109 cells. Int J Mol Med. 2012;30:797–804. doi: 10.3892/ijmm.2012.1085. [DOI] [PubMed] [Google Scholar]
- 17.Harding HP, Zhang Y, Zeng H, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell. 2003;11:619–633. doi: 10.1016/s1097-2765(03)00105-9. [DOI] [PubMed] [Google Scholar]
- 18.Cho S-Y, Lee J-H, Bae H-D, et al. Transglutaminase 2 inhibits apoptosis induced by calcium overload through down-regulation of Bax. Exp Mol Med. 2010;42:639–650. doi: 10.3858/emm.2010.42.9.063. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Jang GY, Jeon JH, Cho SY, et al. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells. Oncogene. 2009;29:356–367. doi: 10.1038/onc.2009.342. [DOI] [PubMed] [Google Scholar]
- 20.Choi K, Siegel M, Piper JL, et al. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol. 2005;12:469–475. doi: 10.1016/j.chembiol.2005.02.007. [DOI] [PubMed] [Google Scholar]
- 21.Jeon JH, Choi KH, Cho SY, et al. Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine. EMBO J. 2003;22:5273–5282. doi: 10.1093/emboj/cdg495. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci. 2002;27:534–539. doi: 10.1016/s0968-0004(02)02182-5. [DOI] [PubMed] [Google Scholar]
- 23.Caccamo D, Condello S, Ferlazzo N, Currò M, Griffin M, Ientile R. Transglutaminase 2 interaction with small heat shock proteins mediate cell survival upon excitotoxic stress. Amino Acids. 2013;44:151–159. doi: 10.1007/s00726-011-1083-z. [DOI] [PubMed] [Google Scholar]
- 24.Kweon SM, Lee ZW, Yi SJ, et al. Protective role of tissue transglutaminase in the cell death induced by TNF-alpha in SH-SY5Y neuroblastoma cells. J Biochem Mol Biol. 2004;37:185–191. doi: 10.5483/bmbrep.2004.37.2.185. [DOI] [PubMed] [Google Scholar]
- 25.Wakshlag JJ, Antonyak MA, Boehm JE, Boehm K, Cerione RA. Effects of tissue transglutaminase on beta-amyloid1–42-induced apoptosis. Protein J. 2006;25:83–94. doi: 10.1007/s10930-006-0009-1. [DOI] [PubMed] [Google Scholar]
- 26.Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol. 2005;6:328–340. doi: 10.1038/nrm1619. [DOI] [PubMed] [Google Scholar]
- 27.Muszbek L, Bereczky Z, Bagoly Z, Komáromi I, Katona É. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011;91:931–972. doi: 10.1152/physrev.00016.2010. [DOI] [PubMed] [Google Scholar]
- 28.Mukherjee DC, Agrawal AK, Manjunath R, Mukherjee AB. Suppression of epididymal sperm antigenicity in the rabbit by uteroglobin and transglutaminase in vitro. Science. 1983;219:989–991. doi: 10.1126/science.6130601. [DOI] [PubMed] [Google Scholar]
- 29.Lee S-M, Jeong EM, Jeong J, et al. Cysteamine prevents the development of lens opacity in a rat model of selenite-induced cataract. Invest Ophthalmol Vis Sci. 2012;53:1452–1459. doi: 10.1167/iovs.11-8636. [DOI] [PubMed] [Google Scholar]
- 30.Király R, Demény M, Fésüs L. Protein transamidation by transglutaminase 2 in cells: a disputed Ca2+-dependent action of a multifunctional protein. FEBS J. 2011;278:4717–4739. doi: 10.1111/j.1742-4658.2011.08345.x. [DOI] [PubMed] [Google Scholar]
- 31.Sue Menko A. Lens epithelial cell differentiation. Exp Eye Res. 2002;75:485–490. doi: 10.1006/exer.2002.2057. [DOI] [PubMed] [Google Scholar]
- 32.Junn E, Ronchetti RD, Quezado MM, Kim SY, Mouradian MM. Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA. 2003;100:2047–2052. doi: 10.1073/pnas.0438021100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Karpuj MV, Becher MW, Springer JE, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med. 2002;8:143–149. doi: 10.1038/nm0202-143. [DOI] [PubMed] [Google Scholar]
- 34.Mastroberardino PG, Iannicola C, Nardacci R, et al. ‘Tissue’ transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington’s disease. Cell Death Differ. 2002;9:873–880. doi: 10.1038/sj.cdd.4401093. [DOI] [PubMed] [Google Scholar]